Renovos and Caltag at BRS/BORS Cardiff

Renovos stand in Cardiff

Working with Caltag Medsystems at BRS/BORS 2019 to spead the word about Renovos and our mesenchymal stem cell products.

Together with Hannah from Caltag Medsystems, Renovos participated in Bone Research Society and British Orthopaedic Research Society combined conference in Cardiff, where the team had the change to mingle with orthopaedic and musculoskeletal researchers and clinicians.

Renovos provides the wider research community with high quality, bone marrow-derived mesenchymal stem cells from elderly and osteoarthritic donor cohorts.

These cells can be used to test and screen novel drugs and biomaterials as well as provide insights into the biology of the musculoskeletal system.

For more information on our products please read here (external link) >

 

Renovos Biologics has appointed Simon Sinclair as non-executive director

Simon Sinclair

Previously in clinical trials at Merck & Co. Inc. and in medical affairs at DePuy Synthes and Johnson & Johnson, Simon is now working in safety and vigilance at RB. This wealth of experience provides Simon with the knowledge within the orthopedic and tissue regeneration fields that Renovos is within, allowing Simon to guide Renovos with its product development, safety testing, clinical trials, and commercialisation.

When asked why he decided to join Renovos – a regenerative medicine start up – Simon responded with “Having contributed to the world of orthopaedic innovation in previous roles, Renovos stood out to me as an exceptional example. What really motivated me to join Renovos was the prospect of realising that innovative potential and bringing safer, better and more cost-effective surgical solutions to patients worldwide.”

It is exciting for Renovos to welcome someone with such experience onto the team and we are looking forward to not only working with Simon but also to the advances we can make with his support.

Impact White Paper

injectable nanoclay

Harnessing clay for regenerative medicine

An Impact white paper

 

Jon Dawson and Richard Oreffo have written a white paper on the nanoclay platform for Impact. In particular they share their thoughts and experiences with the nanoclay platform. Such as how the nanoclay platform can and will be used in the regenerative medicine field.

This Impact white paper provides an exciting overview into the technology. Furthermore, should you be more interested do visit our technical papers page.

The ESPRC and Innovate UK have provided funding to Jon Dawson and Richard Oreffo. Because of this funding research was able to be carried out to ensure the maximum effectiveness of the nanoclay platform.


Harnessing Clay for Regenerative Medicine PDF download
A white paper discussing the field of regenerative medicine, and the usefulness, current limitation of, and future of the nanoclay platform.

Renovos at The Royal Society of Chemistry

exhibit stand

On the 15th October Renovos took part in a Royal Society of Chemistry event called Chemistry means Business. This event is the flagship event for companies which are around Renovos’ size across the UK and Europe. Within the Chemistry means business competition Renovos were finalists in the Health category of the Emerging technologies competition.

This provided a great opportunity for Renovos to show off it’s products of skeletal stem cells, and nanoclays, as well as Renovos’ future plans. Interact with other companies around our size, and learn more about the field.

Read more about the event (external link) >

Renovos Launches Innovate UK Grant!

pipette and gel

We are excited to announce that we have launched our grant from Innovate UK!

Innovate UK is a public body that aims to support the development of science and technology businesses towards commercial success. Helping with company launch or growth through funding and connections, the UK’s innovation agency identifies and fosters innovation in specific areas of interest that promote economic growth.

Our grant has been provided for innovation in Health and Life Sciences, which addresses ideas that will improve, amongst others, healthcare in the UK.

At Renovos, the Innovate UK grant will help us to bring research developments from University of Southampton research groups into the hospital clinic. We’ll begin by advancing work with our nanoclay gel technology that aims to promote faster and more efficient bone healing. This will open up a very real path to regenerative medicine therapies and helping your body to heal itself! It will be thrilling to see our biomaterial be translated into a commercial product for bone healing through Renovos! Excitingly, we have the potential in the future to develop our nanoclay to aid with many more clinical problems, such as within drug delivery.

We are delighted to start this project, would like to thank Innovate UK and look forward to updating you all on our progress in the near future!